Hospital
ST Lukes Community Development Corporation - Sugar Land
ST Lukes Community Development Corporation - Sugar Land was paid $2.85M by Medicaid between Oct 2020 and Nov 2024, across 31 billing codes. Its largest line is 99284, emergency room visit (serious) — 65% of everything it billed.
33Billing provider infoST LUKES COMMUNITY DEVELOPMENT CORPORATION - SUGAR LAND
SUGAR LAND, TX 77478
SUGAR LAND, TX 77478
33aNPI1659559573assigned 02/01/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.85M
24GClaims28,592
24DCodes billed31
24AFirst – last monthOct 2020 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#44 of 109
Median peer was paid$1.15M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 326 | $89K | |
| 2021 | 7,491 | $968K | |
| 2022 | 8,122 | $755K | |
| 2023 | 8,750 | $840K | |
| 2024incomplete | 3,903 | $201K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 65% | 3,456 | 3,197 | $1.85M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 5,162 | 4,941 | $761K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 305 | 281 | $71K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 521 | 507 | $34K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 4,174 | 3,664 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 343 | 301 | $17K |
| 87400 | <1% | 710 | 352 | $13K | |
| 71045 | Radiologic examination, chest; single view | <1% | 492 | 450 | $13K |
| 80053 | Comprehensive metabolic panel | <1% | 1,433 | 1,226 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 387 | 360 | $10K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 419 | 407 | $7K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 87 | 82 | $6K |
19 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 986 | $6K |
| 87807 | <1% | 303 | $5K | |
| 81001 | <1% | 1,335 | $4K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 27 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15 | $2K |
| 81025 | <1% | 129 | $2K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 56 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 52 | $1K |
| 84484 | <1% | 469 | $1K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 16 | $386.76 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 26 | $337.23 |
| 87081 | <1% | 26 | $240.51 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 205 | $216.85 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,584 | $139.71 |
| 85610 | <1% | 44 | $88.08 | |
| 82947 | <1% | 23 | $3.14 | |
| A9270 | Non-covered item or service | <1% | 4,737 | $0.83 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 43 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARGIS, BRYAN (CHIEF EXECUTIVE OFFICER)
Parent organizationST. LUKES EPISCOPAL HEALTH SYSTEM CORPORATION